Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200593460> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4200593460 endingPage "S604" @default.
- W4200593460 startingPage "S603" @default.
- W4200593460 abstract "Abstract Background Molecular rapid diagnostic tests (RDTs) for bloodstream infections (BSI) utilize a variety of technologies and differ substantially in organisms and resistance mechanisms detected. RDT platforms decrease time to optimal antibiotics; however, data on RDTs in special populations, such as immunocompromised are extremely limited. This study aimed to compare theoretical changes in antibiotics based on differences in panel identification of organisms and resistance targets among three commercially available RDT panels. Methods Retrospective cohort of immunocompromised patients treated for gram-negative BSI at University of Maryland Medical Center from January 2018 to September 2020. Immunocompromised was defined as active hematologic or solid tumor malignancy at time of BSI diagnosis, history of hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT), or absolute neutrophil count (ANC) < 1000 cells/mm3 at any time 30 days prior to BSI diagnosis. Verigene BC-GN was performed as standard of care. GenMark ePlex BCID and BioFire FilmArray BCID 2 results were assigned based on respective identifiable organism panels. An infectious diseases clinician blinded to final antimicrobial susceptibility testing (AST) results used RDT results to assign antibiotic treatments for each platform. Decisions were referenced against a priori DOOR-MAT matrices. A partial credit scoring system (0 to 100) was applied to each decision based on final AST results. The mean and standard deviation (SD) were compared across panels using One-Way Repeated Measures ANOVA with modified Bonferroni for multiple comparisons. Results A total of 146 patients met inclusion. Baseline characteristics are summarized in Table 1. The mean (SD) DOOR-MAT scores for the three RDT panels were: 86.1 (24.4) Verigene BC-GN vs. 88.5 (22.2) GenMark BCID vs. 87.2 (24.4) BioFire BCID 2. There was no statistically significant difference between the panels for DOOR-MAT score (P=0.6). Table 1. Baseline Patient Characteristics and Organism Identification Conclusion Within an immunocompromised patient population, differences in organism identification between three commercially available RDT panels did not impact theoretical antibiotic prescribing. Disclosures J. Kristie Johnson, PhD, D(ABMM), GenMark (Speaker’s Bureau) Kimberly C. Claeys, PharmD, GenMark (Speaker’s Bureau)" @default.
- W4200593460 created "2021-12-31" @default.
- W4200593460 creator A5017969903 @default.
- W4200593460 creator A5050273917 @default.
- W4200593460 creator A5053013067 @default.
- W4200593460 creator A5073613133 @default.
- W4200593460 creator A5077727449 @default.
- W4200593460 date "2021-11-01" @default.
- W4200593460 modified "2023-10-17" @default.
- W4200593460 title "1024. Using DOOR-MAT to Theoretically Compare Three Rapid Diagnostic Tests for Gram-Negative Bloodstream Infections in Immunocompromised Patients" @default.
- W4200593460 doi "https://doi.org/10.1093/ofid/ofab466.1218" @default.
- W4200593460 hasPublicationYear "2021" @default.
- W4200593460 type Work @default.
- W4200593460 citedByCount "0" @default.
- W4200593460 crossrefType "journal-article" @default.
- W4200593460 hasAuthorship W4200593460A5017969903 @default.
- W4200593460 hasAuthorship W4200593460A5050273917 @default.
- W4200593460 hasAuthorship W4200593460A5053013067 @default.
- W4200593460 hasAuthorship W4200593460A5073613133 @default.
- W4200593460 hasAuthorship W4200593460A5077727449 @default.
- W4200593460 hasBestOaLocation W42005934601 @default.
- W4200593460 hasConcept C126322002 @default.
- W4200593460 hasConcept C2777063308 @default.
- W4200593460 hasConcept C2777408962 @default.
- W4200593460 hasConcept C2778850193 @default.
- W4200593460 hasConcept C2779399171 @default.
- W4200593460 hasConcept C2909984355 @default.
- W4200593460 hasConcept C2911091166 @default.
- W4200593460 hasConcept C29730261 @default.
- W4200593460 hasConcept C3018946976 @default.
- W4200593460 hasConcept C71924100 @default.
- W4200593460 hasConcept C72563966 @default.
- W4200593460 hasConceptScore W4200593460C126322002 @default.
- W4200593460 hasConceptScore W4200593460C2777063308 @default.
- W4200593460 hasConceptScore W4200593460C2777408962 @default.
- W4200593460 hasConceptScore W4200593460C2778850193 @default.
- W4200593460 hasConceptScore W4200593460C2779399171 @default.
- W4200593460 hasConceptScore W4200593460C2909984355 @default.
- W4200593460 hasConceptScore W4200593460C2911091166 @default.
- W4200593460 hasConceptScore W4200593460C29730261 @default.
- W4200593460 hasConceptScore W4200593460C3018946976 @default.
- W4200593460 hasConceptScore W4200593460C71924100 @default.
- W4200593460 hasConceptScore W4200593460C72563966 @default.
- W4200593460 hasIssue "Supplement_1" @default.
- W4200593460 hasLocation W42005934601 @default.
- W4200593460 hasLocation W42005934602 @default.
- W4200593460 hasOpenAccess W4200593460 @default.
- W4200593460 hasPrimaryLocation W42005934601 @default.
- W4200593460 hasRelatedWork W2006701655 @default.
- W4200593460 hasRelatedWork W2061898233 @default.
- W4200593460 hasRelatedWork W2082620508 @default.
- W4200593460 hasRelatedWork W2518416620 @default.
- W4200593460 hasRelatedWork W2584678776 @default.
- W4200593460 hasRelatedWork W2905956412 @default.
- W4200593460 hasRelatedWork W2982203957 @default.
- W4200593460 hasRelatedWork W3119212226 @default.
- W4200593460 hasRelatedWork W4213365051 @default.
- W4200593460 hasRelatedWork W4256269636 @default.
- W4200593460 hasVolume "8" @default.
- W4200593460 isParatext "false" @default.
- W4200593460 isRetracted "false" @default.
- W4200593460 workType "article" @default.